Zensun Got New Investment to Accelerate Phase III Clinical Trial of rhNRG-1
Zensun signed refinancing contract with a local investment company recently. This investment will be specifically used for Chinese phase III clinical trial of rhNRG-1. So far, the survival study of phase II clinical trial has enrolled more than half of patients. We believe this investment will accelerate our phase III clinical trial and promote Zensun’s new round of refinancing.